Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

390 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence, clinical manifestations and characterization of Enterovirus in the last decade (2014-2023) in Asturias (Spain). Effect of the SARS-CoV-2 pandemic.
Rojo-Alba S, González-Alba JM, Martínez ZP, Varela CO, Álvarez MAA, Fernández PR, Pérez MR, García EG, Boga JA, García SM, Álvarez-Argüelles ME. Rojo-Alba S, et al. Among authors: alvarez maa. Eur J Clin Microbiol Infect Dis. 2024 Nov 15. doi: 10.1007/s10096-024-04970-0. Online ahead of print. Eur J Clin Microbiol Infect Dis. 2024. PMID: 39546098
The Mitragyna speciosa (kratom) alkaloid mitragynine: Analysis of adrenergic α2 receptor activity in vitro and in vivo.
Obeng S, Crowley ML, Mottinelli M, León F, Zuarth Gonzalez JD, Chen Y, Gamez-Jimenez LR, Restrepo LF, Ho NP, Patel A, Martins Rocha J, Alvarez MA, Thadisetti AM, Park CR, Pallares VLC, Milner MJ, Canal CE, Hampson AJ, McCurdy CR, McMahon LR, Wilkerson JL, Hiranita T. Obeng S, et al. Among authors: alvarez ma. Eur J Pharmacol. 2024 Oct 5;980:176863. doi: 10.1016/j.ejphar.2024.176863. Epub 2024 Jul 26. Eur J Pharmacol. 2024. PMID: 39068978 Free PMC article.
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.
Puig N, Agulló C, Contreras T, Pérez JJ, Aires I, Calasanz MJ, García-Sanz R, Castro S, Martínez-López J, Rodríguez-Otero P, González-Calle V, González MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Álvarez MÁ, Bargay J, González-Rodríguez AP, Alegre A, Escalante F, Iñigo MB, De la Rubia J, Teruel AI, De Arriba F, Palomera L, Hernández MT, López-Jiménez J, Reinoso M, García-Mateo A, Ocio EM, Bladé J, Lahuerta JJ, Cedena MT, Paiva B, Miguel JFS, Mateos MV. Puig N, et al. Among authors: alvarez ma. Haematologica. 2024 Dec 1;109(12):4056-4066. doi: 10.3324/haematol.2024.285742. Haematologica. 2024. PMID: 38988266 Free PMC article. Clinical Trial.
390 results